The Precision Promise Trial
Dr. Simeone is the national principal investigator leading Pancreatic Cancer Action Network's (PanCAN) Precision Promise, a groundbreaking adaptive clinical trial platform developed to accelerate approval of new treatment options for pancreatic cancer patients.
This novel clinical trial platform is designed to more efficiently test new therapies for their effectiveness in treating patients with pancreatic cancer by requiring fewer patients to understand if a potential new therapy is working. The platform is also designed to allow multiple investigational therapies to be tested simultaneously. Eligible metastatic pancreatic cancer patients may have the opportunity to receive both first- and second-line treatment options in one clinical trial, and as a late-stage drug development platform, the potential for new drug approvals is built into the model.
Traditional clinical trial designs are slow to evaluate new treatment options for pancreatic cancer. But patients cannot wait: in the United States, nearly 57,000 people will be diagnosed with pancreatic cancer this year, and an estimated 65 percent of patients die within the first year of diagnosis. With PanCAN’s Precision Promise adaptive clinical trial, learning will occur as much as 70 percent faster than with traditional pancreatic cancer clinical trials. NYU Langone is the first of 15 best-in-class medical institutions and cancer research centers nationwide to begin enrolling pancreatic cancer patients in Precision Promise.
The Pancreatic Cancer Early Detection (PRECEDE) Consortium
PRECEDE is an international, multi-institutional collaborative effort to increase survival for pancreatic cancer by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer. It is the largest effort of its kind and utilizes a novel model of collaboration and data sharing. PRECEDE’s mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 9% to 50% within the next 10 years.